NCT06597695 is a Phase 1, PHASE2 clinical trial of Ketamine-assisted psychotherapy in Depression, sponsored by Juliana Zambrano, MD, MPH.

Who is sponsoring NCT06597695?

NCT06597695 is sponsored by Juliana Zambrano, MD, MPH.

What drugs are being tested in NCT06597695?

Interventions in NCT06597695: Ketamine-assisted psychotherapy.

What condition does NCT06597695 study?

NCT06597695 studies Depression.

Is NCT06597695 still recruiting?

NCT06597695 is currently recruiting now. Last updated 28 July 2025.

Last reviewed 2025-07-28 · How we verify

NCT06597695

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression

Recruiting now Phase 1, PHASE2 Last updated 28 July 2025

What this trial tests

Phase 1, PHASE2 trial testing Ketamine-assisted psychotherapy in Depression in 10 participants. Currently enrolling.

Timeline

23 July 2025

Primary endpoint
1 July 2026

1 July 2026

Quick facts

Lead sponsor	Juliana Zambrano, MD, MPH
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	10
Start date	23 July 2025
Primary completion	1 July 2026
Estimated completion	1 July 2026
Sites	1 location across United States

Drugs / interventions tested

Ketamine-assisted psychotherapy — full drug profile →

Conditions studied

Depression — all drugs for Depression →

Sponsor

Juliana Zambrano, MD, MPH — full company profile →

Who can join

Adults 18 to 64, any sex, with Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot clinical trial to assess the feasibility, safety, and preliminary efficacy of ketamine-assisted group therapy for Spanish-speaking adults with depression

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ketamine-assisted psychotherapy

Trials testing the same drug.

NCT05193318 — KAP for Depression in Abstinent Opioid Users · Phase 2 · terminated

Other recruiting trials for Depression

Currently open trials in the same condition.

NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
NCT07517549 — Sexual Health Education During Pregnancy · NA · recruiting
NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06597695 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Juliana Zambrano, MD, MPH
Last refreshed: 28 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06597695.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing